menu
    • menu
    [{"orgOrder":0,"company":"BioPharmX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase IV","graph3":"BioPharmX","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"BioPharmX \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"BioPharmX \/ Undisclosed"},{"orgOrder":0,"company":"BioPharmX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase IV","graph3":"BioPharmX","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"BioPharmX \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"BioPharmX \/ Undisclosed"},{"orgOrder":0,"company":"BioPharmX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase II","graph3":"BioPharmX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"BioPharmX \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioPharmX \/ Undisclosed"},{"orgOrder":0,"company":"BioPharmX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase II","graph3":"BioPharmX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"BioPharmX \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioPharmX \/ Undisclosed"},{"orgOrder":0,"company":"BioPharmX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase IV","graph3":"BioPharmX","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioPharmX \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"BioPharmX \/ Undisclosed"},{"orgOrder":0,"company":"BioPharmX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"BPX-01","moa":"Protein Biosynthesis","graph1":"Dermatology","graph2":"Phase II","graph3":"BioPharmX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"BioPharmX \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioPharmX \/ Undisclosed"},{"orgOrder":0,"company":"BioPharmX","sponsor":"Timber Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Merger","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"BioPharmX","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Ointment","sponsorNew":"BioPharmX \/ BioPharmX","highestDevelopmentStatusID":"10","companyTruncated":"BioPharmX \/ BioPharmX"},{"orgOrder":0,"company":"BioPharmX","sponsor":"Timber Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Merger","leadProduct":"Isotretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"BioPharmX","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Ointment","sponsorNew":"BioPharmX \/ BioPharmX","highestDevelopmentStatusID":"10","companyTruncated":"BioPharmX \/ BioPharmX"},{"orgOrder":0,"company":"BioPharmX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Violet Molecular Iodine (I2)","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"BioPharmX","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioPharmX \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BioPharmX \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by BioPharmX

    Menu

    BioPharmX

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BioPharmX

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            BioPharmX

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isotretinoin

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Recipient : Timber Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Timber Pharmaceuticals Announces Merger Closing

                            Details : The combined company will have a robust pipeline including Timber's two Phase 2b programs and a preclinical program targeting multiple niche orphan indications with no approved treatments as well as BioPharmX's two Phase 3-ready topical minocycline progr...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 18, 2020

                            Lead Product(s) : Isotretinoin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Recipient : Timber Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BioPharmX

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            BioPharmX

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isotretinoin

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Recipient : Timber Pharmaceuticals

                            Deal Size : $20.0 million

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            BioPharmX And Timber Pharmaceuticals Announce Entry into Merger Agreement

                            Details : Under the terms of the merger agreement, a wholly-owned subsidiary of BioPharmX will be merged with and into Timber, with Timber surviving the merger as a wholly-owned subsidiary of BioPharmX.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            January 28, 2020

                            Lead Product(s) : Isotretinoin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Recipient : Timber Pharmaceuticals

                            Deal Size : $20.0 million

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BioPharmX

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            BioPharmX

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Minocycline Hydrochloride

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea

                            Details : Minocycline is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rosacea.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 12, 2018

                            Lead Product(s) : Minocycline Hydrochloride

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            BioPharmX

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            BioPharmX

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Minocycline Hydrochloride

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Open Label Phase 2 Feasibility Study of BPX-04 Topical Minocycline Gel in Rosacea

                            Details : Minocycline is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Rosacea.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 10, 2017

                            Lead Product(s) : Minocycline Hydrochloride

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            BioPharmX

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            BioPharmX

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Minocycline Hydrochloride

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel

                            Details : Minocycline is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Acne Vulgaris.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 27, 2016

                            Lead Product(s) : Minocycline Hydrochloride

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            BioPharmX

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            BioPharmX

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Minocycline Hydrochloride

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris

                            Details : Minocycline is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Acne Vulgaris.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 28, 2016

                            Lead Product(s) : Minocycline Hydrochloride

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            BioPharmX

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            BioPharmX

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BPX-01

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes

                            Details : BPX-01 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Acne Vulgaris.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 15, 2016

                            Lead Product(s) : BPX-01

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            BioPharmX

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            BioPharmX

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Minocycline Hydrochloride

                            Therapeutic Area : Dermatology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Administration of Oral Extended Release Minocycline for Assessment of Skin and Plasma Concentrations of Minocy...

                            Details : Minocycline is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Acne Vulgaris.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 01, 2016

                            Lead Product(s) : Minocycline Hydrochloride

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            BioPharmX

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            BioPharmX

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Violet Molecular Iodine (I2)

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Randomized Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Pot...

                            Details : Violet Molecular Iodine (I2) is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Fibrocystic Breast Disease.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 08, 2016

                            Lead Product(s) : Violet Molecular Iodine (I2)

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth